Vildagliptin API

Vildagliptin API

Vildagliptin is recommended for the treatment of people with type II diabetes mellitus. Vildagliptin is recommended for use as monotherapy in people who cannot manage their weight with diet and exercise alone and for whom metformin is ineffective owing to contraindications or intolerance. It is also recommended as a dual treatment for adult patients with inadequate glycemic control despite receiving the maximum tolerable dose of monotherapy when combined with metformin, sulphonylurea, or thiazolidinedione. For the treatment of people with type II diabetes mellitus who do not react well to either vildagliptin monotherapy or metformin monotherapy, vildagliptin is also used as a combination product with [metformin].

When diet and exercise alone are insufficient to achieve optimal glycemic control in adults, this fixed-dose formulation can be administered in conjunction with a sulphonylurea or insulin (i.e., triple treatment).

*Products will not be offered for sale in countries where valid Patents are in force.
* It is the responsibility of the buyer to comply with the above.